Navigation Links
Virus might fight brain tumors better if armed with bacterial enzyme, study shows

COLUMBUS, Ohio New research shows that oncolytic viruses, which are engineered to destroy cancer cells, might be more effective in treating deadly brain tumors if equipped with an enzyme that helps them penetrate the tumor.

The enzyme, called chondroitinase, helps the cancer-killing virus clear its way through the thickets of protein molecules that fill space between cells and impede the virus's movement through the tumor, say researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute who conducted the study.

When tested in animals transplanted with a human glioblastoma, the most common and deadly form of brain cancer, the enzyme-armed virus improved survival by 52 percent compared with controls and in some cases eliminated the tumor entirely.

The findings were published online in the journal Clinical Cancer Research.

"Our results show for the first time that an oncolytic virus with this enzyme can spread more effectively through the tumor and underscores the potential of using chondroitinases to enhance the capacity of oncolytic viruses to destroy cancer cells," says study leader Balveen Kaur, associate professor of neurological surgery.

The enzyme is derived from the intestinal bacterium called Proteus vulgaris. The enzyme removes sugar chains that branch from molecules called proteoglycans, which fill the narrow spaces between cells. By cutting away these branches, the enzyme clears a path that helps the virus spread through the tumor.

During this study, Kaur and her collaborators injected human glioblastoma cells under the skin of eight animals, and then, after tumors developed, treated the tumors with the enzyme-armed virus. These mice survived an average of 28 days, with two remaining tumor-free after 80 days. Control animals, treated with a virus that lacked the enzyme, survived 16 days.

In another experiment, mice with human gliobastomas transplanted into the brain survived 32 days versus 21 days for control animals, an improvement of 52 percent. Again, two animals lived more than 80 days and showed no trace of the tumor afterward.

Additional studies showed that the enzyme-laden virus had penetrated tumors in the animals' brain significantly better than the enzyme-free control virus.

"Overall, our results indicate that an oncolytic virus armed with this enzyme can have a significantly greater anticancer effect compared with a similar virus without the enzyme," Kaur says.


Contact: Darrell E. Ward
Ohio State University Medical Center

Related medicine news :

1. Scientists decode secrets of a very common virus that can cause cancer
2. Flu Viruses Gaining Resistance, Study Confirms
3. Influenza virus strains show increasing drug resistance and ability to spread
4. BUSM researchers show an oncolytic virus switches off cancer cell survival signal
5. Potential new treatment for deadly nipah and hendra viruses identified by Weill Cornell researchers
6. Scientists investigate evolution of new polio virus
7. Haptoglobin as an early serum biomarker of virus-induced type 1 diabetes in rats
8. New Virus Jumps From Monkey to Scientist, Causing Serious Illness
9. A redeeming role for a common virus
10. Childhood Obesity Might Be Linked to Strain of Cold Virus
11. Higher incidence of seizures seen in children with H1N1 virus compared to seasonal flu
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... The Multiple System Atrophy Coalition has announced the launch of ... (MSA) research, timed today to coincide with Giving Tuesday 2015, a global day of ... to work and be productive, to do simple daily activities like walking to the ...
(Date:12/1/2015)... ME (PRWEB) , ... December 01, 2015 , ... Royal ... reports a new study that found post-menopausal women who took the nutritional supplement creatine, ... than women who trained but did not take creatine. , The report is part ...
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, ... expansion of the company’s growing product line of food safety and seafood fraud ... Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015   MabVax Therapeutics Holdings, Inc . ... it has filed an Investigational New Drug Application (IND) ... the Company,s lead fully human antibody product HuMab 5B1 ... plans to initiate the Phase I clinical trial early ... --> The planned Phase I trial will evaluate ...
(Date:12/1/2015)... , Dec. 1, 2015   Craneware, Inc ... cycle solutions, today announced the company will showcase ... ChargeLink ® solution at the American ... Clinical Meeting . The new features are focused ... of monitoring and managing enterprise-wide pharmacy charges to ...
(Date:12/1/2015)... , Dec. 01, 2015 ... of the "Medical Alert Systems/Personal Emergency Response ... by Geography - Global Forecas" report to ... announced the addition of the "Medical Alert ... by End-User and by Geography - Global Forecas" ...
Breaking Medicine Technology: